Moxifloxacin Activates the SOS Response in Mycobacterium tuberculosis in a Dose- and Time-Dependent Manner

Previous studies on Escherichia coli demonstrated that sub-minimum inhibitory concentration (MIC) of fluoroquinolones induced the SOS response, increasing drug tolerance. We characterized the transcriptional response to moxifloxacin in Mycobacterium tuberculosis. Reference strain H37Rv was treated with moxifloxacin and gene expression studied by qRT-PCR. Five SOS regulon genes, recA, lexA, dnaE2, Rv3074 and Rv3776, were induced in a dose- and time-dependent manner. A range of moxifloxacin concentrations induced recA, with a peak observed at 2 × MIC (0.25 μg/mL) after 16 h. Another seven SOS responses and three DNA repair genes were significantly induced by moxifloxacin. Induction of recA by moxifloxacin was higher in log-phase than in early- and stationary-phase cells, and absent in dormant bacilli. Furthermore, in an H37Rv fluoroquinolone-resistant mutant carrying the D94G mutation in the gyrA gene, the SOS response was induced at drug concentrations higher than the mutant MIC value. The 2 × MIC of moxifloxacin determined no significant changes in gene expression in a panel of 32 genes, except for up-regulation of the relK toxin and of Rv3290c and Rv2517c, two persistence-related genes. Overall, our data show that activation of the SOS response by moxifloxacin, a likely link to increased mutation rate and persister formation, is time, dose, physiological state and, possibly, MIC dependent.

[1]  Yashwant Kumar,et al.  Conditional Silencing by CRISPRi Reveals the Role of DNA Gyrase in Formation of Drug-Tolerant Persister Population in Mycobacterium tuberculosis , 2019, Front. Cell. Infect. Microbiol..

[2]  F. Giannoni,et al.  Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH , 2016, Antimicrobial Agents and Chemotherapy.

[3]  R. Nair,et al.  De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro , 2016, Antimicrobial Agents and Chemotherapy.

[4]  N. Osheroff,et al.  Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase , 2016, Proceedings of the National Academy of Sciences.

[5]  Razieh Pourahmad Jaktaji,et al.  Overexpression of SOS genes in ciprofloxacin resistant Escherichia coli mutants. , 2016, Gene.

[6]  M. Cox,et al.  P1 Ref Endonuclease: A Molecular Mechanism for Phage-Enhanced Antibiotic Lethality , 2016, PLoS genetics.

[7]  P. Genevaux,et al.  Multiple Toxin-Antitoxin Systems in Mycobacterium tuberculosis , 2014, Toxins.

[8]  F. Giannoni,et al.  Activities of Drug Combinations against Mycobacterium tuberculosis Grown in Aerobic and Hypoxic Acidic Conditions , 2013, Antimicrobial Agents and Chemotherapy.

[9]  M. Hatherill,et al.  Moxifloxacin Population Pharmacokinetics in Patients with Pulmonary Tuberculosis and the Effect of Intermittent High-Dose Rifapentine , 2012, Antimicrobial Agents and Chemotherapy.

[10]  S. Kaufmann,et al.  Mycobacterium tuberculosis: success through dormancy. , 2012, FEMS microbiology reviews.

[11]  E. Rubin,et al.  Characterization and Transcriptome Analysis of Mycobacterium tuberculosis Persisters , 2011, mBio.

[12]  M. Vulić,et al.  Ciprofloxacin Causes Persister Formation by Inducing the TisB toxin in Escherichia coli , 2010, PLoS biology.

[13]  M. Vulić,et al.  SOS Response Induces Persistence to Fluoroquinolones in Escherichia coli , 2009, PLoS genetics.

[14]  J. Hinds,et al.  Mycobacterium tuberculosis DNA repair in response to subinhibitory concentrations of ciprofloxacin. , 2008, The Journal of antimicrobial chemotherapy.

[15]  S. Kowalczykowski,et al.  RecBCD Enzyme and the Repair of Double-Stranded DNA Breaks , 2008, Microbiology and Molecular Biology Reviews.

[16]  G. Orefici,et al.  Evaluation of a New Line Probe Assay for Rapid Identification of gyrA Mutations in Mycobacterium tuberculosis , 2005, Antimicrobial Agents and Chemotherapy.

[17]  K. Gerdes,et al.  Prokaryotic toxin–antitoxin stress response loci , 2005, Nature Reviews Microbiology.

[18]  Clifton E. Barry,et al.  DnaE2 Polymerase Contributes to In Vivo Survival and the Emergence of Drug Resistance in Mycobacterium tuberculosis , 2003, Cell.

[19]  L. Rand,et al.  Definition of the Mycobacterial SOS Box and Use To Identify LexA-Regulated Genes in Mycobacterium tuberculosis , 2002, Journal of bacteriology.

[20]  F. Movahedzadeh,et al.  Identification of Some DNA Damage-Inducible Genes of Mycobacterium tuberculosis: Apparent Lack of Correlation with LexA Binding , 2001, Journal of bacteriology.

[21]  L. Wayne,et al.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence , 1996, Infection and immunity.